AS 201
Alternative Names: AS-201Latest Information Update: 06 Oct 2020
At a glance
- Originator AcuraStem
- Class Antidementias; Small molecules
- Mechanism of Action PIKFYVE protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Dementia
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 24 Sep 2020 AS 201 is available for licensing as of 24 Sep 2020. https://acurastem.com/contact/contact-us (Acurastem website, September 2020)
- 24 Sep 2020 Acurastem has patents pending worldwide for PIKFYVE kinase inhibitors (Acurastem website, September 2020)
- 24 Sep 2020 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) before September 2020 (Acurastem pipeline, September 2020)